ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Connexin43 Deficiency Leads to Ventricular Arrhythmias by Reprogramming Proline Metabolism.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supramolecular self-assembled polyphenol nanoparticles alleviate osteoarthritis by inhibiting chondrocyte ferroptosis.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ventricular arrhythmias (VAs) as life-threatening heart rhythm disorders, reduced connexin43 (Cx43) is one of the mechanisms of VAs. Cx43 is the predominant ventricular gap junction protein essential for cardiac electrical conduction; the absence in the mouse heart results in sudden arrhythmic death. However, the mechanism linking Cx43 downregulation and VA formation remains unclear. Here it is aimed to elucidate the molecular mechanism by which Cx43 deficiency leads to VAs using Cx43 knockout (Cx43-KO) induced pluripotent stem-derived cardiomyocytes and cardiac-specific conditional Cx43-KO (Cx43-cKO) mice. It is shown that Cx43-KO induced arrhythmic phenotype and decreased proline content both in vitro and in vivo. Mechanistically, Cx43 interacts with the amino acid transporter SNAT2 (sodium-dependent neutral amino acid transporter). Cx43 deficiency reduces SNAT2 expression, impairing proline transport and metabolism. This disruption leads to mitochondrial dysfunction, oxidative stress, abnormal calcium handling, and arrhythmias. Exogenous proline supplementation rescued the arrhythmic phenotype in Cx43-cKO mice by restoring metabolic balance. In conclusion, it is suggested that Cx43 deficiency leads to VAs through SNAT2-mediated proline metabolic reprogramming. Targeting proline metabolism may therefore offer novel therapeutic strategies for VAs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.